PALO ALTO, Calif., June 10 Telik, Inc.(Nasdaq: TELK), announced today that the European Patent Office has issuednotices of allowance for two applications covering new compounds related toone of Telik's lead clinical candidates, TELINTRA(R). Correspondingapplications have already issued as patents in the United States; and otherapplications are pending in major countries worldwide.
TELINTRA is currently in Phase 2 clinical trials for the treatment ofMyelodysplastic Syndrome, a form of pre-leukemia, and for Chemotherapy InducedNeutropenia, a common side effect of chemotherapy. Telik expects theseapplications and patents to provide broad intellectual property protection tocompounds related to TELINTRA, according to Derek Freyberg, Ph.D., Telik's VP,Intellectual Property. The patents will help to broaden and strengthenTelik's intellectual property estate and may support additional clinicaldevelopment candidates.
Telik, Inc. of Palo Alto, California, is a biopharmaceutical companyfocused on discovering, developing and commercializing novel small moleculedrugs to treat serious diseases. The company's most advanced investigationaldrug candidates in clinical development are TELINTRA, a modified glutathioneanalog for the treatment of cytopenias due to myelodysplastic syndrome orchemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment ofadvanced ovarian cancer and non-small cell lung cancer. Telik's productcandidates were discovered using its proprietary drug discovery technology,TRAP(R), which enables the rapid and efficient discovery of small moleculedrug candidates.
This press release contains "forward-looking" statements, includingstatements regarding the impact and coverage of patents on Telik'sintellectual property. These forward-looking statements are based uponTelik's current expectations. There are important factors that could causeTelik's results to differ materially from those indicated by theseforward-looking statements, including, among others, if clinical trials ofTELINTRA are delayed or unsuccessful, Telik's business would suffer, ifTelik's competitors develop and market products that are more effective thanits product candidates, or obtain marketing approval before Telik does,Telik's commercial opportunity will be reduced or eliminated, and if Telikdoes not obtain regulatory approval to market products in the U.S. and foreigncountries, Telik will not be permitted to commercialize these productcandidates. Detailed information regarding factors that may cause actualresults to differ materially from the results expressed or implied bystatements in this press release may be found in Telik's periodic filings withthe Securities and Exchange Commission, including the factors described in thesection entitled "Risk Factors" in its quarterly report on Form 10-Q for thequarter ended March 31, 2008. Telik does not undertake any obligation toupdate forward-looking statements contained in this press release.
TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks orregistered trademarks of Telik, Inc.
SOURCE Telik, Inc.